Corticosteroids and ICU Course of Community Acquired Pneumonia in Egyptian Settings

Nirmeen A. Sabry, Emad El-Din Omar

.

DOI: 10.4236/pp.2011.22009                

Abstract

Background: Pneumonia is the most common cause of community-acquired infection requiring ICU admission. 60-87% of patients with severe community acquired pneumonia (CAP) admitted to the ICU develops respiratory failure and require mechanical ventilation (MV). Objectives: To assess the efficacy and safety of adjunctive low dose hydrocortisone infusion treatment in Egyptian ICU patients with CAP. Methods: Hospitalized patients, clinically and radiologically diagnosed with CAP, were randomized to receive hydrocortisone 12.5 mg/h IV infusion for 7 days or placebo, along with antibiotics. The end-points of the study were improvement in PaO2:FIO2 (PaO2:FIO2 > 300 or ≥100 increase from study entry) and SOFA score by study day 8 and the development of delayed septic shock. Results: 80 patients were recruited, 40 of them received hydrocortisone and the remaining 40 received placebo. By study day 8, hydrocortisone treated patients showed a significant improvement in PaO2:FIO2 and chest radiograph score, and a significant reduction in C-reactive protein (CRP) levels, Sepsis-related Organ Failure Assessment (SOFA) score, and delayed septic shock compared to the control group. Hydrocortisone treatment was associated with a significant reduction in the duration of MV. However, hydrocortisone infusion did not show significant difference in the ICU mortality. Conclusions: adjunctive 7-day course of low dose hydrocortisone IV in patients with CAP hastens recovery of pneumonia and prevents the development of sepsis related complications with a significant reduction in duration of the mechanical ventilation.

Keywords

Community-Acquired Pneumonia, Corticosteroids, Hydrocortisone, Pneumonia

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. Woodhead, “Community-Acquired Pneumonia,” In: J. Franklin, Ed., Horizons in Medicine, Royal College of Physicians, London, 2004, pp. 165-173.
[2]	“Statistical Abstract of the United States,” 104th Edition, Washington DC, US Government Printing Office, 1984.
[3]	S. H. Feinsilver, A. M. Fein, M. S. Niederman, D. E. Schultz and D. H. Faegenburg “Utility of Fiberoptic Bronchoscopy in Nonresolving Pneumonia,” Chest, Vol. 98, No. 6, 1990, pp. 1322-1326. doi:10.1378/chest.98.6.1322
[4]	M. S. Niederman, L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, F. Martinez, T. J. Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson and V. L. Yu, “Guide Lines for the Management of Adults with Community-Acquired Pneumonia. Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention,” American Journal of Respiratory and Critical Care Medicine, Vol. 163, No. 7, 2001, pp. 1730-1754.
[5]	J. Salluh, P. Póvoa, M. Soares, H. Castro-Faria-Neto, F. Bozza and P. Bozza, “The Role of Corticosteroids in Severe Community-Acquired Pneumonia: A Systematic Review,” Critical Care, Vol. 12, No. 3, 2008, pp. 76-82. doi:10.1186/cc6922
[6]	C. Monton, A. Torres, M. El-Ebiary, X. Filella, A. Xaubet and J. P. De la Bellacasa, “Cytokine Expression in Severe Pneumonia: A Bronchoalveolar Lavage Study,” Critical Care Medicine, Vol. 27, No. 9, 1999, pp. 1745- 1753. doi:10.1097/00003246-199909000-00008
[7]	S. Fernandez-Serrano, J. Dorca, M. Coromines, J. Carratala, F. Gudiol and F. Manresa, “Molecular Inflammatory Responses Measured in Blood of Patients with Severe Community-Acquired Pneumonia,” Clinical and Diagnostic Laboratory Immunology, Vol. 10, No. 5, 2003, pp. 813-820.
[8]	G. Antunes, S. A. Evans, J. L. Lordan and A. J. Frew, “Systemic Cytokine Levels in Community-Acquired Pneumonia and Their Association with Disease Severity,” European Respiratory Journal, Vol. 20, No. 4, 2002, pp. 990-995. doi:10.1183/09031936.02.00295102
[9]	C. Garcia-Vidal, E. Calbo, V. Pascual, C. Ferrer, S. Quintana and J. Garau, “Effects of Systemic Steroids in Patients with Severe Community-Acquired Pneumonia,” European Respiratory Journal, Vol. 30, No. 5, 2007, pp. 951-956. doi:10.1183/09031936.00027607
[10]	H. Schutte, J. Lohmeyer, S. Rosseau, S. Ziegler, C. Siebert, H. Kielisch, H. Pralle, F. Grimminger, H. Morr, and W. Seeger, “Bronchoalveolar and Systemic Cytokine Profiles in Patients with ARDS, Severe Pneumonia and Cardiogenic Pulmonary Oedema,” European Respiratory Journal, Vol. 9, No. 9, 1996, pp. 1858-1867. doi:10.1183/09031936.96.09091858
[11]	R. Mene′ndez, A. Torres, R. Zalacain, J. Aspa, J. J. Martin Villasclaras, L. Borderias, J. M. Benitez Moya, J. Ruiz-Manzano, F. Rodriguez de Castro, J. Blanquer, D. Perez, C. Puzo, F. Sanchez Gascon, J. Gallardo, C Alvarez and L. Molino, “Predictive Factors of Clinical Stability in Community-Acquired Pneumonia,” Thorax, Vol. 59, 2004, pp. 960-965.
[12]	M. Ioanas, M. Ferrer, M. Cavalcanti, .R Ferrer, S. Ewig, X. Filella, J. P. dela Bellacasa and A. Torres, “Causes and Predictors of Nonresponse to Treatment of ICU-Acquired Pneumonia,” Critical Care Medicine, Vol. 32, No. 4, 2004, pp. 938-945. doi:10.1097/01.CCM.0000114580.98396.91
[13]	G. P. Chrouso, “Stressors, Stress, and Neuroendocrine Integration of the Adaptive Response,” The 1997 Hans Selye Memorial Lecture, Annals New York Academy of Sciences, Vol. 851, 1998, pp. 311-335. doi:10.1111/j.1749-6632.1998.tb09006.x
[14]	G. U. Meduri, “An Historical Review of Glucocorticoid Treatment in Sepsis. Disease Pathophysiology and the Design of Treatment Investigation,” Sepsis, Vol. 3, 1999, pp. 21-38. doi:10.1023/A:1009870524359
[15]	P. C. Minneci, K. J. Deans, S. M. Banks, P. Q. Eichacker, and C. Natanson, “Meta-Analysis: The Effect of Steroids on Survival and Shock during Sepsis Depends on the Dose,” Annals of International Medicine, Vol. 141, No. 1, 2004, pp. 47-56.
[16]	P. E. Marik, S. M. Pastores, D. Annane, G. U. Meduri, W. Arlt, C. L. Sprung, D. Keh, J. Briegel, A. Beishuizen, I. Dimopoulou, S. Tsagarakis, M. Singer, G. P. Chrousos, G. Zaloga, F. Bokhari and M. Vogeser, “Clinical Practice Guidelines for the Diagnosis and Management of Corticosteroid Insufficiency in Critical Illness: Recommendations of an International Task Force,” Critical Care Medicine, Vol. 36, No. 6, 2008, pp. 1937-1949. doi:10.1097/CCM.0b013e31817603ba
[17]	M. Mer, and G. A. Richards, “Pneumonia Corticosteroids in Life-Threatening Varicella,” Chest, Vol. 114, No. 2, 1998, pp. 426-431. doi:10.1378/chest.114.2.426
[18]	M. Confalonieri, R. Urbino, A. Potena, M. Piattella, P. Parigi, G. Puccio, R. Della Porta, C. Giorgio, F. Blasi, R. Umberger and G. U. Meduri, “Hydrocortisone Infusion for Severe Community-Acquired Pneumonia: A Preliminary Randomized Study,” American Journal of Respiratory and Critical Care Medicine, Vol. 171, No. 3, 2005, pp. 242-248.
[19]	D. Perla and J. Marmorston, “Suprarenal Cortical Hormone and Salt in the Treatment of Pneumonia and Other Severe Infections,” Endocrinology, Vol. 27, No. 3, 1940, pp. 367-374. doi:10.1210/endo-27-3-367
[20]	S. Ewig, M. Ruiz, J. Mensa, M. A. Marcos, J. A. Martinez, F. Arancibia, M. S. Niederman and A. Torres, “Severe Community-Acquired Pneumonia: Assessment of Severity Criteria,” American Journal of Respiratory and Critical Care Medicine, Vol. 158, No. 4, 1998, pp. 1102-1108.
[21]	J. L. Vincent, R. Moreno, J. Takala, S. Willatts, A. De Mendon?a, H. Bruining, C. K. Reinhart, P. M. Suter, and L. G. Thijs. “The SOFA (Sepsis-Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Fai- lure,” Intensive Care Medicine, Vol. 22, No. 7, 1996, pp. 707-710. doi:10.1007/BF01709751
[22]	G. R. Bernard, A. Artigas, K. L. Brigham, J. Carlet, K. Falke, L. Hudson, M. Lamy, J. R. LeGall, A. Morris and R. Spragg, “The American-European Consensus Conference on ARDS: Definitions, Mechanisms, Relevant Outcomes, and Clinical Trial Coordination,” American Journal of Respiratory and Critical Care Medicine, Vol. 149, No. 3, 1994, pp. 818-24.
[23]	T. Senderovitz and K. Viskun, “Corticosteroids in Tuberculosis,” Respiratory Medicine, Vol. 88, 1994, pp. 561-565. doi:10.1016/S0954-6111(05)80002-2
[24]	S. A. Bozette, F. R. Sattler and J. Chiu, “A Controlled Trial of Early Adjunctive Treatment with Corticosteroids for Pneumocystis Carinii Pneumonia in the Acquired Immunodeficiency Syndrome,” New England Journal of Medicine, Vol. 323, No. 21, 1990, pp. 1451-1457. doi:10.1056/NEJM199011223232104
[25]	R. H. Leavitt and A. S. Fauci, “Pulmonary Vasculitis,” American Review of Respiratory Diseases, Vol. 134, No. 1, 1986, pp. 149-166
[26]	W. K. Bannister, A. J. Sattilano and R. D. Otis, “Therapeutic Aspects of Aspiration Pneumonitis in Experimental Animals,” Anesthiology, Vol. 23, 1961, pp. 440-445. doi:10.1097/00000542-196105000-00017
[27]	C. U. Meduri, S. Headley, S. Carson, et al. “Methylprednisolone Treatment of Late ARDS,” American Journal of Respiratory and Critical Care Medicine, Vol. 155, 1997, p. A391.
[28]	D. Keh, T. Boehnke, S. Weber-Cartens, C. Schulz, O. Ahlers, S. Bercker, H. Volk, W. Doecke, K. J. Falke and H. Gerlach, “Immunologic and Hemodynamic Effects of ‘Low-Dose’ Hydrocortisone in Septic Shock. A Double Blind, Randomized, Placebo-Controlled, Crossover Study,” American Journal of Respiratory and Critical Care Medicine, Vol. 167, No. 4, 2003, pp. 512-520. doi:10.1164/rccm.200205-446OC
[29]	L. A. Mandell, R. G. Wunderink, A Anzueto, J. G. Bartlett, G. D. Campbell, A. Torres and C. G. Whitney, “Guidelines for the Initial Management of Adults with Community-Acquired Pneumonia: Diagnosis, Assessment of Severity, and Initial Antimicrobial Therapy. American Thoracic Society. Medical Section of the American Lung Association,” American Review of Respiratory Diseases, Vol. 148, No. 5, 2007, pp. 1418-1426.
[30]	M. Briel, R. Boscacci, H. Furrer and H. C. Bucher, “Adjunctive Corticosteroids for Pneumocystis Jiroveci Pneumonia in Patients with HIV infection: A Meta-Analysis of Randomized Controlled Trials,” BMC Infectious Diseases, Vol. 5, 2005, p. 101. doi:10.1186/1471-2334-5-101
[31]	J. Puren, C. Feldman, N. Savage, P. J. Becker and C. Smith, “Patterns of Cytokine Expression in Community- Acquired Pneumonia,” Chest, Vol. 107, No. 5, 1995, pp. 1342-1349. doi:10.1378/chest.107.5.1342
[32]	Sibila, C. Agust? and A. Torres, “Corticosteroids in Severe Pneumonia,” European Respiratory Journal, Vol. 32, No. 2, 2008, pp. 259-264. doi:10.1183/09031936.00154107
[33]	S. Yende, E. I. Tuomanen, R. Wunderink, A. Kanaya, A. B. Newman, T. Harris, N. De Rekeneire and S. B. Kritchevsky, “Preinfection Systemic Inflammatory Markers and Risk of Hospitalization Due to Pneumonia,” American Journal of Respiratory and Critical Care Medicine, Vol. 172, No. 11, 2005, pp. 1440-1446. doi:10.1164/rccm.200506-888OC
[34]	C. U. Meduri, “The Role of the Host Defense Response in the Progression and Outcome of ARDS: Pathophysiological Correlations and Response to Gluococorticoid Treatment,” European Respiratory Journal, Vol. 9, No. 12, 1996, pp. 2650-2670. doi:10.1183/09031936.96.09122650
[35]	P. J. Barnes and I. Adcock, “Anti-inflammatory Actions of Steroids: Molecular Mechanisms,” Trends in Pharmacological Sciences, Vol. 14, No. 12, 1993, pp. 436-441. doi:10.1016/0165-6147(93)90184-L
[36]	S. Hong and L. Levine, “Inhibition of Arachidonic Acid Release from Cells as the Biochemical Actions of Anti-Inflammatory Steroids,” Proceedings of the National Academy of Sciences USA, Vol. 73, No. 5, 1976, pp. 1730-1733. doi:10.1073/pnas.73.5.1730
[37]	T. J. K. Toung, D. Bordos, D. W. Benson, D. Carter, G. D. Zuidema, S. Permutt and L. Cameron, “Aspiration Pneumonia: Experimental Evaluation of Albumin and Steroid Therapy,” Annals of Surgery, Vol. 183, No. 2, 1976, pp. 179-184. doi:10.1097/00000658-197602000-00016
[38]	P. E. Bollaert, C. Charpentier, B. Levy, M. Debouverie, G. Audibert and A. Larcan, “Reversal of Late Septic Shock with Supraphysiologic Doses of Hydrocortisone,” Critical Care Medicine, Vol. 26, No. 4, 1998, pp. 645-650. doi:10.1097/00003246-199804000-00010
[39]	K. Chawla, Y. Kupfer, I. Goldman and S. Tessler, “Hydrocortisone Reverses Refractory Septic Shock,” Critical Care Medicine, Vol. 27, No. 1, 1999, p. A33. doi:10.1097/00003246-199901001-00022
[40]	Yildiz, M. Doganay, B. Aygen, M. Guven, F. Keleutimur and A. Tutuu, “Physiological-Dose Steroid Therapy in Sepsis,” Critical Care, Vol. 6, No. 3, 2002, pp. 251-259. doi:10.1186/cc1498
[41]	D. Annane, V. Sebille, C. Charpentier, P. E. Bollaert, B. Francois, J. M. Korach, G. Capellier, Y. Cohen, E. Azoulay, G. Troche, et al., “Effect of Treatment with Low Doses of Hydrocortisone and ?udrocortisone on Mortality in Patients with Septic Shock,” Journal of the American Medical Association, Vol. 288, No. 7, 2002, pp. 862-871. doi:10.1001/jama.288.7.862
[42]	M. A. Jantz and S. A. Sahn, “Corticosteroids in Acute Respiratory Failure,” American Journal of Respiratory and Critical Care Medicine, Vol. 160, No. 4, 1999, pp. 1079-1100.
[43]	P. Marik, P. Kraus, J. Sribante, I. Havlik, J. Lipman and D. W. Johnson, “Hydrocorisone and Tumor Necrosis Factor in Severe Community-Acquired Pneumonia: A Randomized Controlled Study,” Chest, Vol. 104, No. 2, 1993, pp. 389-392. doi:10.1378/chest.104.2.389
[44]	C. Monton, S. Ewig, A. Torres, M. El-Ebiary, X. Filella, A. Rano and A. Xaubet, “Role of Glucocorticoids on Inflammatory Response in Nonimmunosuppressed Patients with Pneumonia: A Pilot Study,” European Respiratory Journal, Vol. 14, No. 1, 1999, pp. 218-220. doi:10.1034/j.1399-3003.1999.14a37.x
[45]	K. Mikami, M. Suzuki, H. Kitagawa, M. Kawakami, N. Hirota, H. Yamaguchi, O. Narumoto, Y. Kichikawa, M. Kawai, H. Tashimo, H. Arai, T. Horiuchi and Y. Sakamoto, “Efficacy of Corticosteroids in the Treatment of Community-Acquired Pneumonia Requiring Hospitalization,” Annals of International Medicine, Vol. 141, 2006, pp. 47-56.
[46]	D. Snijders, M. Johannes, A. Daniels, S. Casper, S. De Graaff, S. Tjip, F. Van der Wer, G. Wim, and A. Boersma, “Efficacy of Corticosteroids in Community-acquired Pneumonia,” American Journal of Respiratory and Critical Care Medicine, Vol. 181, No. 9, 2010, pp. 975-982. doi:10.1164/rccm.200905-0808OC
[47]	C. L. Sprung, D. Annane, D. Keh, R. Moreno, M. Singer, K. Freivogel, Y. G. Weiss, J. Benbenishty, A. Kalenka, H. Forst, P. F. Laterre, K. Reinhart, B. H. Cuthbertson, D. Payen and J. Briegel, “Hydrocortisone Therapy for Patients with Septic Shock,” New England Journal of Medicine, Vol. 358, No. 2, 2008, pp. 111-124. doi:10.1056/NEJMoa071366
[48]	D. Annane, E. Bellissant, P. E. Bollaert, J. Briegel, D. Keh and Y. Kupfer, “Corticosteroids for Severe Sepsis and Septic Shock: A Systematic Review and Meta- Analysis,” British Medical Association Journal, Vol. 329, No. 7464, 2004, pp. 480-488.
[49]	K. P. Steinberg, L. D. Hudson, R. B. Goodman, et al., “Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome,” New England Journal of Medicine, Vol. 354, No. 16, 2006, pp. 1671- 1684.
[50]	B. De Jonghe, T. Sharshar, J. P. Lefaucheur, et al., “Paresis Acquired in the Intensive Care Unit: A Prospective Multicenter Study,” Journal of the American Medical Association, Vol. 288, No. 22, 2002, pp. 2859-2867. doi:10.1001/jama.288.22.2859